- Opioid addictions have reached epidemic proportions in the U.S., with painkiller-related deaths reaching over 20,000 people in 2015 alone.
- Scientists from Scripps Research Institute are conducting preclinical trials to study the use of vaccines to block the effects of various opioid drugs.
- There are questions about the research, including how to manage surgical pain in vaccinated patients, and whether the vaccines will prompt addicts to take massive doses seeking a drug effect.
Highly addictive opioid drugs, including morphine, codeine, oxycodone, and hydrocodone, among others, are not only the most common agents used for pain management throughout the world but also are an increasingly common culprit in today’s epidemic of addiction. It is not only recreational thrill seekers who get into trouble with the opioids. Many addiction problems begin after a painkiller is first prescribed for a legitimate reason such as post-surgical pain.
Premature death from painkiller addiction has reached epic proportions in the United States, with 20,101 overdose deaths from prescription painkillers and 12,990 from heroin in 2015 alone, out of a total of 55,403 fatal drug overdoses.1 Opioid addiction is driving this epidemic, with and has prompted much research into ways to deal with the problem. As reported in The Economist, a group out of the Scripps Research Institute now reports that it has developed an “anti-opioid vaccine.”2
“Chemical Tweaking” Needed to Activate Vaccine
The researchers, led by Kim Janda, PhD, note that opioids do not provoke the immune system in and of themselves, so for the new vaccine to activate antibody production, it must be “chemically tweaked and attached to an appropriate carrier protein.” Dr. Janda believes that difficulties in producing an active vaccine in the past have been because the “haptens,” as the manipulated opioids used in the vaccine are called, are not structurally close enough to the actual drug to provoke a very strong immune system reaction. In the new research, the hapten structure has been made to closely replicate that of the opioids.
This study looked at laboratory mice treated either with an active vaccine or a placebo control, in this case an inert saline solution, then dosed with either hydrocodone or oxycodone. Based on pain reactions of the studied animals, the researchers determined that the vaccinated mice the vaccine was effectively blocking the drug effect. The new vaccine appeared to remain effective for months, and the scientists hope it will prove to last long enough to break an addiction but not so long as to render pain medicine useless in the vaccinated person.
Another finding was that the vaccinated animals appeared to have a reduced risk of death from overdosing. Only 25 percent of deliberately overdosed control mice survived for a day, while 62.5 percent of the vaccinated animals survived that critical 24-hour period. The numbers were lower for both groups treated with oxycodone, but the vaccinated animals still had a better survival rate at 37.5 percent versus 14.2 percent of control animals.
Same Scientist Also Experimenting With Fentanyl Vaccine
In an earlier study, Dr. Janda and his team reported a similar preclinical outcome with an experimental vaccine against fentanyl, a synthetic opioid often used by drug dealers to cut or replace heroin. Said to be 50 to 500 times more potent than morphine, users have no way of gauging the potency of any given dose, which has led to a rash of overdose deaths. The scientists have proposed creating a combination vaccine against fentanyl and heroin, since the two are often seen together.
Like the hydrocodone/oxycodone study, the vaccinated laboratory animals in the fentanyl study did not appear to be affected by the opioid and tolerated 30 times the usual dosage without dying from the overdose. The researchers hope that will help buy time for life-saving treatment (such as with naloxone) if the effect crosses over to human subjects.3 4 They say the fentanyl vaccine acts against any fentanyl derivative, but does not react with other opioid classes such as oxycodone. There is no mention of cross reactivity, or lack thereof, in the newer study against those other opioids. The researchers have noted that, once bound to the antibody, the neutralized drug remains in the body for a long time.5
Many Questions Need to Be Answered
These experimental vaccines are still in early stages of development, but they open up many questions. For example, what happens if a vaccinated individual needs emergency surgery soon after being vaccinated? If the vaccine neutralizes any painkiller, there will be no recourse to treat pain. If, on the other hand, there is no cross-reactivity, it would allow for medical intervention for serious pain, but it also leaves the door open for addicts to move from one opioid to another to bypass the vaccine’s effect.
What will happen if an addicted person overdoses just trying to overcome the effective blockade? How does a manipulated opioid interact with mood-regulating neurotransmitters such as serotonin and dopamine?
1 Opioid Addiction 2016 Facts & Figures. American Society of Addiction Medicine 2016.
2 Souring the poppy’s milk: A long-sought vaccine against opioid drugs may now be on the cards. The Economist Dec. 17, 2016.
3 Scientists Create Vaccine Against Dangerous Designer Opioids. Phys Org Feb. 16, 2016.
4 Bremer PT, et al. Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs. Angewandte Chemie International Edition 2016.
5 Scientists Develop Vaccine Against Fatal Prescription Opioid Overdose. Phys Org Nov. 23, 2016.